Interested in specific Information?

Filter what you see here

Patients non-eligible for transplant

Quick poll

Carfilzomib, cyclophosphamide, and dexamethasone for the treatment of…

Carfilzomib, cyclophosphamide, and dexamethasone for the treatment of transplant-ineligible patients with high-risk multiple myeloma

Closes Apr 7, 2020

General MM

Quick poll

Expert Opinion | Mohamad Mohty: COVID-19 and multiple myeloma

Closes Apr 7, 2020

Relapsed/refractory patients

Quick poll

Results from a phase I study of VLX1570 for patients with…

Closes Mar 31, 2020

General MM

Quick poll

Recommendations for the management of patients with multiple myeloma in…

Recommendations for the management of patients with multiple myeloma in the United States during the COVID-19 pandemic

Closes Mar 30, 2020

Relapsed/refractory patients

Quick poll

Isatuximab combination therapy receives positive opinion from EMA CHMP for…

Closes Mar 30, 2020 , Expert Opinion

General MM

Quick poll

COVID-19 and EBMT recommendations for patients with hematological…

Closes Mar 27, 2020

General MM

Quick poll

Long-term treatment approaches for patients with newly diagnosed multiple…

Long-term treatment approaches for patients with newly diagnosed multiple myeloma

Closes Mar 26, 2020

General MM

Quick poll

The impact of COVID-19 on the management of patients with multiple myeloma

Closes Mar 24, 2020

General MM,   Patients non-eligible for transplant

Quick poll

Optimal dosing of bortezomib in multiple myeloma based on the results of…

Closes Mar 23, 2020 , Expert Opinions

Relapsed/refractory patients,   General MM

Quick poll

Could bendamustine plus dexamethasone be a viable treatment option for R/R…

Could bendamustine plus dexamethasone be a viable treatment option for R/R systemic light-chain amyloidosis?

Closes Mar 18, 2020 , Expert Opinion

General MM

Quick poll

Daratumumab for smoldering multiple myeloma — results from the phase…

Closes Mar 17, 2020 , Expert Opinion

General MM,   Patients non-eligible for transplant,  Patients eligible for transplant

Quick poll

Improving frontline therapies for patients with multiple myeloma

Closes Mar 16, 2020

General MM,   Patients eligible for transplant

Quick poll

Analysis of long-term post auto-SCT outcomes

Analysis of long-term post auto-SCT outcomes

Closes Mar 13, 2020 , Expert Opinion

Patients non-eligible for transplant

Quick poll

ELOQUENT-1 and TOURMALINE-MM2 studies report no improvement in PFS in…

Closes Mar 12, 2020

General MM

Quick poll

GMMG-MM5 | Response-adapted lenalidomide maintenance in newly diagnosed…

Closes Mar 9, 2020
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

Latest Biology

General MM,Relapsed/refractory patients

Cytopenia associated with CAR T-cell therapy

Mar 3, 2020

Latest Drug Updates

Relapsed/refractory patients

Isatuximab combination therapy receives positive opinion from EMA CHMP for the treatment…

Mar 30, 2020 , Expert Opinion

Recently updated Licenses

Where we are next

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

30th August–2nd September, 2020 | Madrid, ES

The Multiple Myeloma Hub will be attending the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Madrid, ES. We will be presenting live coverage via our social media channels, interviewing world-leading experts and providing summaries of key sessions. Stay tuned to follow our first-hand coverage. 

Use the following hashtags on Twitter to join the conversation: #EBMT20 #mmsm #myeloma

Event Website

Map Data
Map data ©2020 Inst. Geogr. Nacional
Map DataMap data ©2020 Inst. Geogr. Nacional
Map data ©2020 Inst. Geogr. Nacional

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology